Jaguar Health registers the resale of 5.48M shares from a $2M Series P financing, potentially diluting shareholders by 52.76% at a $0.546 floor price
JAGX is trading near its 52-week low of $0.95 (5.7% above the low) on elevated volume (1.8× avg).
Summary
Jaguar Health filed a prospectus to register the resale of up to 5.48 million shares from a $2 million Series P Preferred Stock financing. The shares could dilute existing holders by over 52% at a floor price of $0.546, well below the current $1.00 stock price.
Key Events · Financing and Capital Events · JAGX
-
Resale Registration for 5.48M Shares
The prospectus registers up to 5,483,086 shares for resale by selling stockholders from the June 9, 2026 Series P Preferred Stock financing. It includes 4,395,605 Redemption Shares, 32,535 Commencement Shares, and 1,054,946 Dividend Shares.
-
Potential Dilution Exceeds 52%
If all registered shares are issued, outstanding shares would rise from 4.91M to 10.39M, diluting existing holders by 52.76%. The floor price for redemptions and dividends is $0.546, a 45.6% discount to the current $1.0045 stock price.
-
No Proceeds to Company
Jaguar Health will not receive any proceeds from the resale of shares by selling stockholders. The company already received $2 million from the initial private placement of Series P Preferred Stock.
-
Financing Part of Broader Dilutive Pattern
This registration follows stockholder approval on June 8, 2026 of two highly dilutive financing agreements totaling $42.4 million with C/M Capital, and a recent Series O Preferred Stock conversion that issued 4.86 million shares.
Analysis · JAGX · Life Sciences
This prospectus registers the resale of up to 5.48 million shares underlying a $2 million Series P Preferred Stock financing that closed on June 9, 2026. The shares represent over 52% of the current outstanding, with a floor price of $0.546—well below the current $1.0045 stock price. While the company receives no proceeds from resales, the registration enables selling stockholders to liquidate, creating significant overhang. The low floor price and high dilution potential signal a deeply dilutive structure, typical of distressed financing. Against a backdrop of recent going-concern risks and multiple dilutive deals, this filing confirms the terms of a highly shareholder-unfriendly capital raise.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.7% of the 1838 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $0.95 to $92.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.